HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT03510741

Sodium Benzoate for schizophrenia

This study is completed in Pakistan. It is testing sodium Benzoate for schizophrenia.

SchizophreniaDrugFrom 18 Years to 35 Years
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria apply.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 1, 2019
Recruitment status
Completed
Enrollment listed in the registry
64
Sponsor
Pakistan Institute of Living and Learning
Sponsor type
Research institute
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Pakistan
Age range
From 18 Years to 35 Years
Official registry ID
NCT03510741
Official title
A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03510741. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Quetta, Pakistan · Rawalpindi, Pakistan · Karachi, Pakistan

Compensation and expense reimbursement have not been verified for this summary.

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pakistan Institute of Living and Learning, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Sodium Benzoate, N-Acetylcysteine, Placebo and Sodium Benzoate Plus N-Acetylcysteine.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 35 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.